Literature DB >> 2544697

Radiation absorbed dose from technetium-99m-labeled bone imaging agents. Task Group of the Medical Internal Radiation Dose Committee, The Society of Nuclear Medicine.

D A Weber1, P T Makler, E E Watson, J L Coffey, S R Thomas, J London.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2544697

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  5 in total

1.  Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis.

Authors:  Andrew J Einstein; Igor Shuryak; Adam Castaño; Akiva Mintz; Mathew S Maurer; Sabahat Bokhari
Journal:  J Nucl Cardiol       Date:  2018-05-30       Impact factor: 5.952

2.  Tc-99m pyrophosphate imaging for transthyretin cardiac amyloidosis: Importance of estimation of cancer risk with the modality.

Authors:  Shivda Pandey; Omar K Siddiqi
Journal:  J Nucl Cardiol       Date:  2018-07-27       Impact factor: 5.952

Review 3.  Scintigraphy in the clinical evaluation of disorders of mineral and skeletal metabolism in renal failure.

Authors:  F A de Jonge; E K Pauwels; N A Hamdy
Journal:  Eur J Nucl Med       Date:  1991

4.  Quantification of 99mTc-DPD concentration in the lumbar spine with SPECT/CT.

Authors:  Michal Cachovan; Alexander Hans Vija; Joachim Hornegger; Torsten Kuwert
Journal:  EJNMMI Res       Date:  2013-06-05       Impact factor: 3.138

5.  Comparison of the Absorbed Dose for (99m)Tc-Diethylenetriaminepentaacetic Acid and (99m)Tc-Ethylenedicysteine Radiopharmaceuticals using Medical Internal Radiation Dosimetry.

Authors:  Shokufeh Pirdamooie; Ahmad Shanei; Masoud Moslehi
Journal:  J Med Signals Sens       Date:  2015 Jul-Sep
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.